Skip to main content
. 2020 Sep 3;4(17):4113–4123. doi: 10.1182/bloodadvances.2020002184

Table 3.

Summary of outcome

All, % (95% CI) Targeted therapy, % (95% CI) Chemoimmunotherapy, % (95% CI) P
3-y OS 73 (64, 80) 87 (68, 95) 69 (58, 78) .22
3-y PFS 61 (51, 70) 72 (52, 85) 58 (46, 68) .3
3-y NRM 14 (8, 21) 7 (1, 19) 17 (9, 26) .2
3-y relapse 24 (17, 33) 21 (8, 38) 26 (17, 36) .88
6-mo grade III-IV acute GVHD 9 (5, 16) 13 (4, 28) 7.7 (3, 15) .5
1-y chronic GVHD 48 (38, 57) 57 (37, 73) 45 (34, 56) .47